Alnylam and Inceptive Nucleics Join Forces to Advance RNAi Therapeutics with AI
A new partnership between Alnylam and Inceptive Nucleics, valued at up to $2 billion, aims to leverage AI foundation models to enhance RNA interference therapeutics over the next three years.
Alnylam has entered into a significant three-year partnership with Inceptive Nucleics, which could be worth up to $2 billion. This collaboration is set to focus on the development of AI foundation models specifically for RNA interference therapeutics.
As part of the agreement, Alnylam will make an upfront payment of $30 million in cash and equity to Inceptive Nucleics, indicating a strong commitment to this innovative approach.
The partnership reflects a growing trend in biotechnology, where artificial intelligence is increasingly being integrated into therapeutic development to enhance efficacy and outcomes.